Join our mission

We are racing to launch the first phase 3 study for a brain-penetrant NLRP3 inhibitor in the cardiometabolic space. This is just the beginning for our leading portfolio of potent, selective, orally available small molecules which we believe can transform a wide range of therapeutic areas where chronic inflammation plays a role. Join our team of scientists, clinicians and industry leaders working every day to bring the incredible potential of our medicines to patients and their families.

NodThera is an equal opportunity employer. We value a diverse and inclusive work culture for all employees, regardless of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.

Here are our currently open roles:

Director of Clinical Program and Portfolio Management

Location: Remote (UK/Europe)

Head of Technical Operations

Location: Remote (UK preferred) or USA

Vice President, Therapeutic Area Head – CardioMetabolism

Location: Remote (UK preferred) or USA
Headshot of Alan Watt, PhD, MBA, Chief Scientific Officer of NodThera.”
Alan Watt, PhD, MBA 
Founder & Chief Scientific Officer
NodThera is in the first wave of companies to explore the clinical utility of NLRP3 inhibitors. NLRP3 is now one of the most biologically and genetically validated therapeutic targets of our time – the next frontier is employing the chemistry that will inhibit NLRP3.
Alan Watt, PhD, MBA 
Founder & Chief Scientific Officer
Valerie Reader
Vice President of Scientific Operations
NodThera’s cutting-edge, fast-paced and friendly environment makes it a very exciting place to work.
Valerie Reader
Vice President of Scientific Operations